The Addario Lung Cancer Medical Institute (ALCMI) has teamed with Biocept to initiate a clinical trial designed to evaluate the ability of liquid biopsy to detect and assess lung cancer biomarkers. The prospective trial will enroll 400 patients with advanced non-small cell lung cancer. Patients will have 4–6 blood samples drawn over 12 months to create a bank of liquid biopsy data points. The samples will then be tested with Biocept’s Target Selector assay, a platform that analyzes both circulating tumor cells and circulating tumor DNA in blood to detect key biomarkers such as epidermal growth factor receptor, KRAS, and programmed death-ligand 1 expression. The study’s main goal is to establish whether liquid biopsies agree with solid tissue biopsies during de novo presentation. It will also examine the utility of liquid biopsies for assessing drug response, predicting treatment failure, and identifying resistance mechanisms in lung cancer patients.